Application for regulatory approval of apixaban in Europe to be submitted

Editorial Checklist Reviewed
Dec 4 2009NewsGuard 100/100 Score

Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) today announced that the companies are planning to submit an application for regulatory approval of apixaban in Europe for the prevention of venous thromboembolism (VTE) after orthopedic surgery in the first half of 2010. The application will be supported by ADVANCE-2 and ADVANCE-3, two clinical trials that evaluated apixaban versus the European dosing regimen of enoxaparin for prevention of VTE in patients undergoing orthopedic surgery. Results of ADVANCE-2 were first presented in July 2009 at the 22nd Congress of the International Society on Thrombosis and Haemostasis in Boston. The ADVANCE-3 data will be submitted for publication and presentation in 2010.

Apixaban is a novel, oral, highly selective Factor Xa inhibitor, a new class of agents being studied for the potential to prevent and treat blood clots in the veins and arteries.

Source:

http://www.bms.com/

Posted in: Pharmaceutical News

Tags: , , , , , , ,

Comments (0)

Suggested Reading

Low-carb diet may improve beta-cell function in type 2 diabetes patients
3D-printed bone model offers new possibilities for surgery
Researchers boost natural defenses to fight cataracts and delay the need for surgery
Researchers uncover why typically normal protein drives prostate cancer
Repeated fasting for multiple orthopedic surgeries linked to poor recovery outcomes
Are back problems influenced by your gut?
New surgical stitches capable of generating electrical charge may accelerate wound healing
Knee replacement surgery outcomes improve with native alignment approach

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
AI-powered MRI predicts outcomes in prostate cancer